How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. This MRD-focused outcome is particularly important because it informs the accelerated approval pathway for ZENBEXUS...